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Summary
Background—Worldwide data for cancer survival are scarce. We aimed to initiate worldwide 
surveillance of cancer survival by central analysis of population-based registry data, as a metric of 
the effectiveness of health systems, and to inform global policy on cancer control.
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Methods—Individual tumour records were submitted by 279 population-based cancer registries 
in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) 
diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at 
cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in 
adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; 
errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for 
background mortality in every country or region by age (single year), sex, and calendar year, and 
by race or ethnic origin in some countries. Estimates were age-standardised with the International 
Cancer Survival Standard weights.
Findings—5-year survival from colon, rectal, and breast cancers has increased steadily in most 
developed countries. For patients diagnosed during 2005–09, survival for colon and rectal cancer 
reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 
85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for 
both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15–19% in North 
America, and as low as 7–9% in Mongolia and Thailand. Striking rises in 5-year survival from 
prostate cancer have occurred in many countries: survival rose by 10–20% between 1995–99 and 
2005–09 in 22 countries in South America, Asia, and Europe, but survival still varies widely 
around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto 
Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 
50% to more than 70%; regional variations are much wider, and improvements between 1995–99 
and 2005–09 have generally been slight. For women diagnosed with ovarian cancer in 2005–09, 5-
year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 
5-year survival for stomach cancer in 2005–09 was high (54–58%) in Japan and South Korea, 
compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia 
in Japan and South Korea (18–23%) is lower than in most other countries. 5-year survival from 
childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% 
in Canada and four European countries, which suggests major deficiencies in the management of a 
largely curable disease.
Interpretation—International comparison of survival trends reveals very wide differences that 
are likely to be attributable to differences in access to early diagnosis and optimum treatment. 
Continuous worldwide surveillance of cancer survival should become an indispensable source of 
information for cancer patients and researchers and a stimulus for politicians to improve health 
policy and health-care systems.
Funding—Canadian Partnership Against Cancer (Toronto, Canada), Cancer Focus Northern 
Ireland (Belfast, UK), Cancer Institute New South Wales (Sydney, Australia), Cancer Research 
UK (London, UK), Centers for Disease Control and Prevention (Atlanta, GA, USA), Swiss Re 
(London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Cancer League 
(Bern, Switzerland), and University of Kentucky (Lexington, KY, USA).
Introduction
The global burden of cancer is growing, particularly in countries of low and middle income. 
The need to implement effective strategies of primary prevention is urgent.1,2 Prevention is 
crucial but long term. If WHO's global target of a 25% reduction in deaths from cancer and 
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other non-communicable diseases in people aged 30–69 years is to be achieved by 2025 
(referred to as 25 × 25),3 we will need not only more effective prevention (to reduce 
incidence) but also more effective health systems (to improve survival).4
In the first international comparison of cancer survival, a transatlantic study of patients 
diagnosed during 1945–54, survival for 12 cancers in three US states was typically higher 
than in six European countries.5 In 2008, a global comparison of population-based cancer 
survival (CONCORD) showed very wide variations in survival from cancers of the breast 
(women), colon, rectum, and prostate.6 That analysis included 1·9 million adults (age 15–99 
years) diagnosed with cancer during 1990–94 and followed up until 1999 from 31 countries 
(16 with 100% population coverage) on five continents.
Three large international comparisons of cancer survival have been published since 2008. 
The European cancer registry study on survival (EUROCARE)-5 provided survival 
estimates for all cancers for patients diagnosed during 2000–07 in 29 countries in Europe.7 
In SurvCan (cancer survival in Africa, Asia, the Caribbean, and Central America), relative 
survival estimates were reported for patients diagnosed during 1990–2001 in 12 low-income 
and middle-income countries.8 The International Cancer Benchmarking Partnership 
published survival estimates for four common cancers for patients diagnosed during 1995–
2007 in six high-income countries.9 These three studies differ with respect to geographic 
and population coverage, calendar period, and analytical methods and do not enable 
worldwide comparison of cancer survival.
Surveillance of cancer survival is seen as important by national and international agencies, 
cancer patient advocacy groups, departments of health, politicians, and research agencies. 
Cancer survival research is being used to formulate cancer control strategies,9 to prioritise 
cancer control measures,10 and to assess both the effectiveness11,12 and cost-effectiveness13 
of those strategies.
We designed CONCORD-2 to initiate long-term worldwide surveillance of cancer survival 
on the broadest possible basis. Our aim is to analyse progress toward the overarching goal in 
the Union for International Cancer Control's World Cancer Declaration 2013: “there will be 
major reductions in premature deaths from cancer and improvements in quality of life and 
cancer survival”.14
Methods
Cancer registries
We identified population-based cancer registries that were operational in 2009 and had 
either published reports on survival or were known to follow up registered cancer patients to 
establish their vital status. Many registries had met quality criteria for inclusion in either the 
quinquennial compendium Cancer Incidence in Five Continents,15,16 published by the 
International Association of Cancer Registries (IACR) and the International Agency for 
Research on Cancer (IARC), or similar compendia; other registries were established more 
recently.
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We invited all these registries to contribute data for patients diagnosed during all or part of 
the 15-year period 1995–2009, including data on their vital status at least 5 years after 
diagnosis, or at Dec 31, 2009, or a later year. Of 395 registries invited, 306 (77%) agreed to 
participate: of these, 24 (8%) did not submit data, either because of resource constraints 
(n=4), legal constraints (1) or reversal of the original decision (3), or because they could not 
provide complete follow-up data (6) or did not respond to further communication (10). We 
excluded three registries because they provided data that did not adhere to the protocol and 
could not be rectified, leaving 279 participating registries (71% of those invited).
Among the cancers suggested by participating registries, the ten we prioritised for study 
(referred to as index sites) accounted collectively for almost two-thirds of the estimated 
global cancer burden in 2008, both in developed and developing countries.4 They comprised 
cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and 
prostate in adults (age 15–99 years), and leukaemia in adults, and precursor-cell acute 
lymphoblastic leukaemia in children (age 0–14 years).
Ethics approval
We obtained approval for CONCORD-2 from the Ethics and Confidentiality Committee of 
the UK's statutory National Information Governance Board (now the Health Research 
Authority; ECC 3-04(i)/2011) and the National Health Service (NHS) research ethics service 
(southeast; 11/LO/0331). We obtained separate statutory or ethics approval (or both) in more 
than 40 other jurisdictions to secure the release of data. Registries in all other jurisdictions 
obtained their own ethics approval locally.
We applied strict security constraints to the transmission of data files. We gave every 
registry a set of unique numeric codes for the name of every file; these codes have no 
meaning outside the CONCORD-2 study. All data fields were numeric or coded. We 
developed a file transmission utility deploying 256-bit advanced encryption security, with 
random, strong, one-time passwords that were generated automatically at the point of data 
transmission but sent separately, thus eliminating the need for email or telephone exchanges 
to confirm passwords. We also provided free access to a similar commercial utility 
(HyperSend; Covisint, Detroit, MI, USA) that complies with US federal law on the secure 
transmission of sensitive health data.
Protocol
We finalised the protocol (in which we defined the data structure, file transmission 
procedures, and statistical analyses) after a 2-day meeting in Cork, Ireland, in September, 
2012, with 90 members of the CONCORD Working Group from 48 countries (the protocol 
was revised by October, 2012). English poses a communication barrier in many countries; 
therefore, native speakers translated the protocol into Chinese (Mandarin), Portuguese, and 
Spanish, and other native speakers did back-translation to check the translation against the 
English original. We made the protocol available in all four languages. We held protocol 
workshops in Argentina (for Spanish-speaking South American researchers), Brazil, China, 
India, Japan, Puerto Rico, Russia, and the USA (for North America), which we followed up 
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with conference calls and online seminars. We responded to telephone or email queries in 
Chinese, English, French, Italian, Portuguese, and Spanish.
We defined countries, states, and world regions by their UN names and codes (as of 2007).17 
Only Cuba and Puerto Rico provided data from the Caribbean and Central America so we 
grouped them with South America as America (Central and South). We wrote this Article 
and prepared the maps without prejudice to the status, boundaries, or name of any country, 
territory, or region. We have shortened some names for convenience (eg, Korea for South 
Korea), which does not have any political significance. We created world maps and 27 
regional maps in ArcGIS version 10, using digital boundaries (shapefiles) of countries and 
subnational regions from the Database of Global Administrative Areas (GADM 2.0).18 We 
obtained national populations for 2009 from the UN Population Database17 or national 
authorities (Canada, Portugal, and the UK) and subnational populations from the relevant 
registries.
We defined solid tumours by anatomical site (topography) and leukaemia by morphology 
(table 1). We coded topography and morphology according to the International 
Classification of Diseases for Oncology (3rd edn; ICD-O-3).19 For ovarian cancer, we 
included the fallopian tube, uterine ligaments, and adnexa, and the peritoneum and 
retroperitoneum, where high-grade serous ovarian carcinomas are often detected. We 
excluded Kaposi's sarcoma and solid tumours with lymphoma morphology.
The classification of leukaemias and lymphomas has changed since the mid-1990s. To 
minimise differences in the range of leukaemia subtypes included in our analyses, we asked 
registries to provide data for all haemopoietic malignant diseases in adults and children, as 
defined by the ICD-O-3 morphology code range 9590–9989. In consultation with specialists 
in the cancer registry-based project on haematologic malignancies (HAEMACARE) 
group,20 we selected subtypes of adult leukaemia from nine morphology groups,21 
excluding myelodysplastic and myeloproliferative neoplasms such as chronic myeloid 
leukaemia (appendix p 2). Precursor-cell acute lymphoblastic leukaemia is the most 
common form of leukaemia in children; we included HAEMACARE group 15—a relatively 
homogeneous group comprising precursor-cell lymphoblastic lymphoma and precursor-cell 
lymphoblastic leukaemia (B-cell, T-cell, and not otherwise specified), and we refer to these 
six entities as acute lymphoblastic leukaemia.22
For survival analyses, we included only invasive primary malignant diseases (ICD-O-3 
behaviour code 3). To facilitate quality control and comparisons of the intensity of early 
diagnostic and screening activity, however, we asked registries to submit data for all solid 
tumours at each index site, including those that were benign (behaviour code 0), of uncertain 
or borderline malignancy (1), or in situ (2).
We asked registries to submit full dates (day, month, year) for birth, diagnosis, and death or 
last known vital status, both for quality control and to enable comparable estimation of 
survival.23 When the day of diagnosis or the day or month of birth or last known vital status 
were missing, we developed an algorithm to standardise the imputation of missing dates for 
all populations (details available on request). Participating registries completed a detailed 
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question naire on their methods of operation, including data definitions, data collection 
procedures, coding of anatomical site, morphology and behaviour, the tracing of registered 
cancer patients to ascertain their vital status, and how tumour records are linked with data on 
vital status.
We included patients who were diagnosed with two or more primary cancers at different 
index sites during 1995–2009 in the analyses for each cancer—eg, colon cancer in 2000, 
breast cancer in 2005. We measured survival from the date of diagnosis until the date of 
death, or loss to follow-up, or censoring. When two or more primary malignant diseases 
occurred at the same index site during 1995–2009, we included the first cancer only. We 
retained the most complete record for patients with synchronous primary cancers in the same 
organ.
North American registries define multiple primary cancers under the rules of the 
Surveillance, Epidemiology and End Results (SEER) programme,24 whereas registries in the 
European Network of Cancer Registries (ENCR) and elsewhere generally use the rules of 
the IACR,25 which are more conservative. The North American Association of Central 
Cancer Registries (NAACCR) prepared a program to enable all North American registries to 
recode their entire incidence databases to the IACR multiple primary rules, before their 
datasets for 1995–2009 were extracted for CONCORD-2.
Quality control
The quality and completeness of cancer registration data can affect both incidence and 
survival estimates and, thus, the reliability of international comparisons.26 We developed a 
suite of quality control programs,27 extending the checks used in the first CONCORD 
study,6 cross-checked with those used in the EUROCARE study,28 IARC/IACR tools for 
cancer registries,29 and WHO's classification of tumours.22,30–32 We applied these checks 
systematically in three phases and sent registries a detailed report on how to revise and 
resubmit their data, if needed, after every phase.
First, we sent registries a protocol adherence report that showed, for every cancer, the 
proportion of tumour records that were coded in compliance with the protocol. Second, we 
checked the data in every tumour record for logical coherence against 20 sets of criteria, 
including eligibility (eg, age, tumour behaviour), definite errors (eg, sex-site errors and 
invalid dates or date sequence), and possible errors including a wide range of inconsistencies 
between age, tumour site, and morphology.27 We sent registries exclusion reports that 
showed, for every index cancer and calendar period, the number of tumour records in each 
category of definite or possible error, the number of tumours registered from a death 
certificate only or detected at autopsy, and the number of patients whose data could be 
included in survival analyses. When we identified errors in classification, coding, or 
pathological assignment, we asked registries to correct and resubmit their data. Finally, we 
analysed: the proportion of tumour records with morphological verification or non-specific 
morphology; distributions of the day and month of birth, diagnosis, and last known vital 
status; and proportions of patients who died within 30 days, were reported as lost to follow-
up, or were censored within 5 years of diagnosis.
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Follow-up for vital status
Cancer registries use various methods to ascertain the vital status (alive, dead, emigrated, 
lost to follow-up) of registered cancer patients. In countries with limited administrative 
infrastructure, so-called active follow-up can be used to establish vital status via direct 
contact with the patient, the family, or a local authority (eg, a village headman), or by home 
visit. Many registries in both high-income and low-income countries also seek information 
from the hospital or the treating clinician in hospital or primary care.
Most registries link their database with a regional or national index of deaths, using 
identifiers such as name, sex, date of birth, and identity number. Tumour records that match 
to a death record are updated with the date of death. Many registries also use other official 
databases (eg, hospital and primary care databases, social insurance, health insurance, 
drivers’ licences, and electoral registers) to establish the date on which a patient was last 
known or believed to have been alive, to have migrated within the country, or to have 
emigrated to another country. Cancer registrations are updated with the vital status and the 
date of last known vital status. These methods are typically summarised as passive follow-
up.
Some registries receive information on the vital status of all registered patients on an almost 
continuous basis, or at least every month or every 3 months. Other registries seek to trace 
the vital status of patients registered in a particular calendar year only, 1 year or even 5 years 
after the end of that year: this approach can increase the proportion of patients lost to follow-
up. It also means that 5-year survival estimates for more recently diagnosed patients cannot 
be obtained, even with the period approach.
We asked all 279 participating registries how they ascertained the vital status of registered 
cancer patients. Of 243 registries that responded to the question, 147 (60%) stated that they 
used only passive follow-up, 92 (38%) that they used both passive and active follow-up, and 
four (2%) only active follow-up.
Statistical analysis
Most registries submitted data for patients diagnosed from 1995 to 2009, with follow-up to 
2009 or later; some registries only began operation after 1995 or provided data for less than 
15 years. We were able to estimate 5-year survival using the cohort approach for patients 
diagnosed in 1995–99 and 2000–04, because in most datasets, all patients had been followed 
up for at least 5 years. We used the period approach33 to estimate 5-year survival for 
patients diagnosed during 2005–09, because 5 years of follow-up data were not available for 
all patients (appendix p 174).
We estimated net survival up to 5 years after diagnosis for both adults and children. Net 
survival represents the cumulative probability that the cancer patients would have survived a 
given time, say 5 years or more after diagnosis, in the hypothetical situation that the cancer 
was the only possible cause of death. Net survival can be interpreted as the proportion of 
cancer patients who survive up to that time, after eliminating other causes of death 
(background mortality). We used the recently developed Pohar Perme estimator34 of net 
survival implemented with the program stns35 in Stata version 13.36 This estimator takes 
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unbiased account of the fact that older patients are more likely than younger patients to die 
from causes other than cancer—ie, that the competing risks of death are higher for elderly 
cancer patients.
To control for the wide differences in background mortality between participating 
jurisdictions and over time, we constructed 6514 life tables of all-cause mortality in the 
general population of each country or the territory covered by each participating registry, by 
age (single year), sex, and calendar year of death, and by race or ethnic origin in Israel 
(Arab, Jewish), Malaysia (Chinese, Malay, Indian), New Zealand (Māori, non-Māori), and 
the USA (Black, White). The method of life table construction depended on whether we 
received raw data (numbers of deaths and populations) or mortality rates, and on whether the 
raw data or the mortality rates were by single year of age (so-called complete) or by 5-year 
or 10-year age group (abridged). We checked the life tables by examination of age-sex-
mortality rates, life expectancy at birth (appendix p 175), the probability of death in the age 
bands 15–59 years, 60–84 years, and 85–99 years and, where necessary, the model residuals.
Of the 279 participating registries, 21 provided complete life tables that did not need 
interpolation or smoothing, for each calendar year. For 172 registries, we obtained raw data 
from either the registry, the relevant national statistical authority, or the Human Mortality 
Database.37 We derived life tables for 1996 and 2010 if possible, each centred on three 
calendar years of data (eg, 1995–97, 2009–11) to increase the robustness of the rates. We 
modelled raw mortality rates with Poisson regression and flexible functions to obtain 
smoothed complete life tables extended up to age 99 years. We then created life tables for 
every calendar year from 1997 to 2009 by linear interpolation between the 1996 and 2010 
life tables.38 Rather than extrapolate, we used the 1996 life table for 1995.
62 of 279 registries provided abridged mortality rates, or complete mortality rates that were 
not smoothed. We used the Ewbank relational model39 with three or four parameters to 
interpolate (if abridged) and smooth the mortality rates for the registry territory against a 
high-quality smooth life table for a country with a similar pattern of mortality by age. We 
could not obtain reliable data on all-cause mortality for 24 registries. We took national life 
tables published by the UN Population Division40 and interpolated and extended them to age 
99 years with the Elandt-Johnson method.41
For each country and registry, we present estimates of age-standardised net survival for each 
cancer at 5 years after diagnosis. We report cumulative survival probabilities as percentages. 
For adults, we used the International Cancer Survival Standard (ICSS) weights, with age at 
diagnosis categorised into five groups: 15–44 years, 45–54 years, 55–64 years, 65–74 years, 
and 75–99 years for eight solid tumours and leukaemia in adults; and 15–54 years, 55–64 
years, 65–74 years, 75–84 years, and 85–99 years for prostate cancer.42 For children, we 
estimated survival for the age groups 0–4 years, 5–9 years, and 10–14 years; we obtained 
age-standardised estimates by assigning equal weights to the three age-specific estimates.43 
We derived CIs for both unstandardised and age-standardised survival estimates assuming a 
normal distribution, truncated to the range 0–100. We derived SEs with the Greenwood 
method44 to construct the CIs
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We did not estimate survival if fewer than ten patients were available for analysis. If 
between ten and 49 patients were available for analysis in a given calendar period (1995–99, 
2000–04, 2005–09), we merged data for two consecutive periods. For less common cancers 
in the smallest populations, we sometimes needed to merge data for all three periods. When 
between ten and 49 patients in total were available, we only estimated survival for all ages 
combined. If 50 or more patients were available, we attempted survival estimation for each 
age group. If an age-specific estimate could not be obtained, we merged data for adjacent 
age groups and assigned the combined estimate to both age groups. If two or more age-
specific estimates could not be obtained, we present only the unstandardised estimate for all 
ages combined.
Role of the funding sources
The funders had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all data in the study and 
had final responsibility for the decision to submit for publication.
Results
279 cancer registries from 67 countries provided data for this study (figure 1; appendix pp 
112–40). Nine African countries took part (ten registries), eight countries were in Central 
and South America (27 registries), Canada and the USA comprised North America (57 
registries), 16 countries were in Asia (50 registries), 30 European countries participated (128 
registries), and New Zealand and Australia represented Oceania (seven registries). For 
countries with less than 100% coverage of the population, the country name is used for 
brevity in the text (eg, Libya, the USA), but a more accurate term is used in the tables (eg, 
Libya [Benghazi], US registries). Some registries provided data for only part of their 
territory.
We examined records for 28 685 445 patients diagnosed with cancer of the stomach, colon, 
rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults (age 15–99 years), 
leukaemia in adults, and precursor-cell acute lymphoblastic leukaemia in children (age 0–14 
years) during the period 1995–2009 (table 2). Of these, 1 682 081 (5·9%) records were for 
an in situ cancer, mostly of the cervix, breast, colon, or prostate. The proportions of in situ 
cancer are not comparable directly because some registries do not record in situ cancer, 
others did not submit data for index sites in which in situ malignant disease is common, and 
screening programmes in which in situ cancers are frequently detected were introduced in 
some countries during 1995–2009. The variation between continents is still of interest: for 
example, a little over 1% of cervical cancers in African registries were in situ, compared 
with 20% in Central and South American registries and 81% in Oceania. For breast cancer 
in situ, the variation was from 0·1% in African registries to 16% in North American 
registries and about 4–5% in other regions of the world (appendix pp 3–63). Patients with in 
situ cancer were not included in survival analyses.
We excluded a further 360 773 (1·3%) patients either because their year of birth, month or 
year of diagnosis, or year of last vital status were unknown, or because the tumour was not 
primary invasive malignant disease (behaviour code 3) or the morphology was that of 
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Kaposi's sarcoma or lymphoma in a solid organ, or for other reasons (table 2). The 
proportion of patients with an unknown date of last vital status ranged from 0% to 40% or 
more for some cancers in some African registries. Proportions are presented in the appendix 
(pp 3–63) for each registry, for all cancers combined, and for each cancer separately.
Of 26 642 591 patients eligible for inclusion in the survival analyses, 905 841 (3·4%) were 
excluded because their cancer was registered from a death certificate only or discovered at 
autopsy (table 2), and 59 863 (0·2%) were excluded for other reasons, including definite 
errors (eg, unknown vital status or sex, sex-site error, or invalid dates or sequence of dates) 
or possible errors (eg, apparent inconsistencies between age, cancer site, and morphology) 
for which the record was not later confirmed as correct by the relevant registry.
Of 25 676 887 patients available for survival analyses (96·4% of those eligible), pathological 
evidence of malignant disease (histological, cytological, or haematological findings) was 
available for 23 338 015 patients for all cancers combined (91·1%; table 2), ranging from 
83·1% in Asian registries, 85·5% in African registries, and 87·4% in Central and South 
American registries to 90–95% in Europe, Oceania, and North America. The range of 
pathological evidence at a national level was very wide, from 15% in The Gambia, 36% in 
Mongolia, and 66% in Chinese registries, up to 99% or more in Belgium, Mauritius, and 
Sweden. For 938 703 (3·7%) patients, morphological features were poorly specified (eg, 
malignant neoplasm or tumour, ICD-O-3 codes 8000–8005): this proportion also varied 
widely, from around 1% in North American registries to 17% for all African registries 
combined and as high as 59% in The Gambia. Data for every registry are shown in the 
appendix (pp 3–63).
Morphological confirmation for each cancer varied widely between continents and 
countries. Overall, 48·2% of liver cancers had morphological data available compared with 
84·4% of lung cancers, at least 90% of other solid tumours and adult leukaemia, and 99% of 
childhood acute lymphoblastic leukaemia (appendix pp 3–63). Morphological confirmation 
was available for 100% of acute lymphoblastic leukaemias in all the specialist childhood 
cancer registries, including the national registries in Lesotho and Belarus.
The 279 participating cancer registries represented an estimated total population of about 
896 210 000 people in 2009, or 18·6% of the combined national populations of the 67 
countries (4·8 billion total population; table 3); details by registry are provided in the 
appendix (pp 64–80). 100% coverage of the national population was provided by 40 
countries. Population coverage in Australia was 91%, and in the USA it was 83%. In the 
remaining 25 countries, population coverage ranged from 0·5% to 47%. In China, 21 
participating registries covered 37·7 million people (2·8% of 1·35 billion total population), 
whereas the four registries in India covered 5·9 million people (0·5% of 1·19 billion total 
population). China and India apart, data from 254 registries covered 37% of the combined 
population of 2·3 billion people in 65 countries.
Life expectancy at birth in 2009 varied widely between the 279 registry populations: for 
females, the range was 46–87 years and for males it was 45–81 years (appendix, p 175). Life 
expectancy rose slightly from 1995 to 2009 in most populations, but in some countries it 
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changed substantially between the earliest and latest years for which data were available, 
from a decline of 6–9 years in South Africa and Lesotho (attributable largely to HIV/
AIDS),45 to an increase of 6 years or more in Estonia, Latvia (for males), and South Korea, 
and in some regions of Brazil (males), China, and Germany (males; data not shown).
Whenever possible, findings are presented for patients diagnosed during 1995–99, 2000–04, 
and 2005–09, by continent, country, and registry (figures 2 to 4; appendix pp 3–173). When 
data were available for more than one registry in a given country, survival estimates were 
derived by pooling data for that country, excluding data from registries for which estimates 
were judged less reliable (figures 2 and 3). Survival estimates were flagged as less reliable if 
a higher than usual proportion of patients was excluded from analyses because their cancer 
was registered from the death certificate only, or had an unknown date for last vital status, or 
because not all deaths were ascertained. Less reliable estimates are not always outliers in the 
global distribution, but when they are, they have been omitted from this discussion. Less 
reliable estimates are also excluded from the distribution of survival among registries in 
each continent (figure 4).
Data for stomach cancer are available for 1 645 596 patients. 191 registries in 48 countries 
contributed data for 1995–99, 241 registries in 56 countries provided data for 2000–04, and 
241 registries in 59 countries provided data for 2005–09 (table 3; appendix pp 64–80). For 
patients diagnosed during 2005–09, age-standardised 5-year net survival for stomach cancer 
was very high in South Korea (58%), Japan (54%), and Mauritius (41%; table 4; appendix p 
142). 5-year survival from stomach cancer was 30–39% in Austria, Belgium, China, 
Germany, Iceland, Italy, Portugal, Switzerland, and Taiwan. 5-year survival in Denmark, 
Malta, Poland, and the UK was lower than in most other European countries (18–19%). 
Survival was less than 10% in Gibraltar and Libya, but those two estimates are based on 
fewer than 100 cases (table 4; appendix pp 64–80). In most countries, survival from stomach 
cancer remained in the narrow range of 25–30% from 1995–99 to 2005–09. Very large 
increases were seen in South Korea (from 33% to 58%) and China (from 15% to 31%), but 
survival rose by less than 10% in some countries on all continents (appendix p 153). 
Survival from stomach cancer fell by 6–17% in Brazil, Cyprus, Malaysia, Thailand, and 
Turkey, declines that were not seen for most other cancers in these registries. We could not 
assess survival trends for stomach cancer in African countries. The range of 5-year survival 
estimates for stomach cancer in 2005–09 varied widely between registries in Africa, Asia, 
and Central and South America (appendix p 164).
Data for colon cancer are available for 3 613 067 patients (table 3). 191 registries in 48 
countries contributed data for 1995–99, 244 registries in 58 countries provided data for 
2000–04, and 242 registries in 61 countries had data for 2005–09 (appendix pp 64–80). For 
patients diagnosed with colon cancer during 2005–09, age-standardised 5-year net survival 
was 50–59% in many countries, although it did surpass 60% in North America, Oceania, 12 
European countries, and a few countries in Central and South America and Asia (table 4; 
appendix p 143). 5-year net survival from colon cancer was 40–49% in Argentina, Bulgaria, 
Chile, Colombia, Latvia, and Russia, and it was less than 40% in India, Indonesia, and 
Mongolia. In most countries, 5-year survival from colon cancer increased from 1995–99 to 
2005–09, but it fell in Argentina and Cyprus (table 4; appendix p 154). Pooled 5-year 
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survival estimates for Canada and the USA were already high (57% and 61%, respectively) 
for patients diagnosed with colon cancer in 1995–99, but they increased to 63% and 65%, 
respectively, for individuals diagnosed during 2005–09. Data were generally available from 
the same registries throughout the period 1995–2009 in North America and Oceania, where 
survival from colon cancer was either stable or improving, and the range of estimates was 
narrow (appendix p 165). High outlier values for 2005–09 are for Yukon (Canada; 78%, a 
merged estimate based on 109 cases) and Australian Capital Territory (Australia; 74%, 
based on 247 cases; appendix pp 64–111).
Data for rectal cancer are available for 1 413 861 patients (table 3). 188 registries in 46 
countries provided data for 1995–99, 240 registries in 57 countries had data available for 
2000–04, and 238 registries in 60 countries contributed data for 2005–09 (appendix pp 64–
80). For patients diagnosed with cancer of the rectum during 2005–09, age-standardised 5-
year net survival was in the range 50–59% in many countries. Survival was very high (70% 
or more) in Cyprus, Iceland, and Qatar, and high (60–69%) in South Korea, North America, 
Oceania, and nine European countries (table 4; appendix p 144). Survival from rectal cancer 
was very low in India (29%). During 1995–2009, survival from rectal cancer increased in 
most countries, but it was stable or even falling in Argentina, Brazil, Chile, India 
(Karunagappally), Malaysia, and Uruguay (appendix p 155).
Data for liver cancer are available for 894 449 patients (table 3). 189 registries in 46 
countries contributed data for 1995–99, 236 registries in 54 countries provided data for 
2000–04, and 236 registries in 57 countries had data available for 2005–09 (appendix pp 64–
80). However, international comparisons are more limited for liver cancer than for other 
malignant diseases because estimates from 20 countries were flagged as less reliable, mainly 
because of a high proportion of cancer registrations from a death certificate only (appendix 
pp 24–28). Age-standardised 5-year net survival from liver cancer was generally low (10–
20%) in most countries, both in the developed and developing world, throughout the period 
1995–2009 (table 4; appendix p 145). Survival only reached 20% or more for patients 
diagnosed during 2005–09 in some east Asian countries (Japan, South Korea, and Taiwan), 
where a steady rise in survival from liver cancer has been seen since 1995–99. Even for 
2005–09, survival was still very low (less than 10%) in Colombia, Denmark, Estonia, 
Finland, India, Malta, Mongolia, Norway, Russia, Slovenia, Thailand, and the UK. 
Estimates judged less reliable were mostly very similar to those that were robust. 5-year 
survival from liver cancer increased between 1995–99 and 2005–09 in the two countries in 
North America, four countries in Asia, and 13 European countries. Survival declined in 
Thailand from 16% to 8% (based on 14 800 cases). The high survival estimate for Mauritius 
(53%) is a national figure, but it is based on only 23 cases and is not age-standardised.
Data for lung cancer are available for 5 294 261 patients (table 3). 190 registries in 48 
countries provided data for 1995–99, 240 registries in 57 countries contributed data for 
2000–04, and 240 registries in 60 countries had data available for 2005–09 (appendix pp 64–
80). Age-standardised 5-year net survival from lung cancer was typically low, in the range 
10–20% for most geographical areas, both in the developed and developing world (table 4, 
appendix pp 146 and 168). The general pattern is very similar to that of liver cancer. 
International variation in survival is less striking than for cancers with good prognosis, but 
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differences are still noticeable. For patients diagnosed during 2005–09, 5-year survival from 
lung cancer was higher than 20% in only three countries: Japan (30%), Israel (24%), and 
Mauritius (37%). The survival estimate for Mauritius is based on only 84 cases diagnosed in 
2005 (appendix pp 64–80). Survival from lung cancer was very low (less than 10%) in 
Bulgaria, Lithuania, Mongolia, and Thailand, and only 2% in Libya (Benghazi; based on 
317 patients diagnosed during 2003–05). Between 1995–99 and 2005–09, survival from 
lung cancer rose by 7% in Israel and Japan, and it increased in China (from 8% to 18%), 
India (Karunagappally; from 4% to 10%; appendix pp 81–111) and South Korea (from 10% 
to 19%). Rises of 2–4% were noted in Colombia, North America, and Europe. Survival from 
lung cancer fell from 19% to 10% in Turkey (Izmir), but this reduction could be attributable 
to improvement in data quality. Smaller decreases (2–4%) were seen in Cyprus, Croatia, 
Malaysia, and Lithuania.
Data for breast cancer are available for 5 486 928 women (table 3). 193 registries in 49 
countries provided data for 1995–99, 245 registries in 57 countries had data available for 
2000–04, and 243 registries in 59 countries contributed data for 2005–09 (appendix pp 64–
80). Most survival estimates were judged reliable. For women diagnosed during 2005–09, 
age-standardised 5-year net survival from breast cancer was 80% or higher in 34 countries 
around the world (table 4, figures 2 to 4). However, breast cancer survival was lower than 
70% in Malaysia (68%) and India (60%) and very low in Mongolia (57%) and South Africa 
(53%). Between 1995–99 and 2005–09, survival from breast cancer increased in Central and 
South America, particularly in Brazil (from 78% to 87%), Colombia (from 66% to 76%), 
and Ecuador (from 69% to 83%; figure 3). Survival also rose in Algeria (from 17% to 60%), 
but this trend is less reliable. We were unable to assess survival trends in most other African 
countries. The very low survival estimate for breast cancer in Mali (13·6%; Bamako) is not 
age-standardised and is a pooled estimate based on 203 women diagnosed during 1995–
2004. These women represent only a small proportion of all those registered with breast 
cancer in this period; for most women, obtaining information on their vital status proved 
impossible. In North America and Oceania, survival from breast cancer was high, with a 
fairly narrow range between registries (84–89%) and with stable or slightly improving 
survival seen up to 2005–09. Survival also rose in Europe but was generally lower than in 
North America and Oceania and with a much wider geographic range (figure 4).
Data for cervical cancer are available for 602 225 women (table 3). 192 registries in 51 
countries provided data for 1995–99, 244 registries in 58 countries contributed data for 
2000–04, and 244 registries in 61 countries provided data for 2005–09 (appendix pp 64–80). 
The global range in 5-year net survival from cervical cancer is very wide, particularly in 
Africa, Central and South America, and Asia (table 4; appendix p 169). For women 
diagnosed with cancer of the cervix during 2005–09, age-standardised 5-year net survival 
was 70% or higher in Iceland, Mauritius, Norway, South Korea, and Taiwan; the estimate 
for Qatar is also above 70% but is based on only 16 cases and is not age-standardised (table 
4; appendix p 147). In 34 of 61 countries around the world, 5-year survival was in the range 
60–69%. In general, cervical cancer survival was 50% or higher in all other countries, 
except for Libya (Benghazi, 39%) and India (Karunagappally, 46%). Survival estimates for 
northeast India (Guwahati, 32%; Sikkim, 53%) are flagged as less reliable because up to 
30% of women could not be traced despite active follow-up (appendix pp 39–43). Survival 
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for cervical cancer is stable or has increased slightly in most countries (appendix p 158). For 
example, in Central and South America, survival was stable at around 60% in Brazil, Cuba, 
Ecuador, and Puerto Rico. In the 10 years between 1995–99 and 2005–09, 5-year net 
survival increased from 42% to 51% in Chile and from 46% to 51% in Argentina. In France, 
the decline in survival between 1995–99 and 2000–04 (from 66% to 61%) was based on 
around 1700 women in each period; the survival estimate for women diagnosed during 
2005–09 (59%) includes data for only 139 women from two registries (Calvados, 76%; 
Loire-Atlantique, 49%); the other registries could not provide follow-up data for women 
diagnosed with cervical cancer after 2004 (appendix pp 64–80). The striking increase in 5-
year survival from cervical cancer in China (from 40% to 60%) should be interpreted with 
caution: the estimate for 1995–99 is based on data for only 71 women in Changle, Jiashan, 
and Zhongshan, whereas the estimates for 2000–04 (56%) and 2005–09 (60%) are based on 
data for more than 1200 women (18 registries) and 3900 women (21 registries), respectively 
(appendix pp 64–111).
Data for ovarian cancer are available for 779 302 women (table 3). 191 registries in 48 
countries contributed data for 1995–99, 243 registries in 57 countries had data available for 
2000–04, and 241 registries in 61 countries provided data for 2005–09 (appendix pp 64–80). 
For women diagnosed with ovarian cancer during 2005–09, age-standardised 5-year net 
survival was 40% or higher in Ecuador, the USA, nine countries in Asia, and eight countries 
in Europe (table 4; appendix p 148). Survival in other countries was mostly in the range 30–
40%, except for Libya (22%). The high survival estimate for Gibraltar (59%) is based on 
data for only 13 women; it is not age-standardised and the CI is wide (table 4); similarly, the 
very high estimate for Mauritius (83%) is based on 52 women diagnosed in 2005. 5-year 
survival for ovarian cancer rose by more than 10% between 1995–99 and 2005–09 in 
Ecuador (from 35% to 47%), Estonia (from 28% to 39%), and Japan (from 26% to 37%), 
and by 5–10% in Bulgaria, Denmark, France, Hong Kong, Iceland, Latvia, and Portugal 
(appendix p 159). More modest increases (2–4%) were seen in several countries in South 
America, Asia, and Europe. We were unable to assess any trend in Africa because of scant 
reliable data covering the entire period 1995–2009. For women diagnosed with ovarian 
cancer since 2000, data were available from 60 registries in Asia and Central and South 
America (appendix p 170). The range in 5-year survival was very wide. The range is much 
narrower for the 160 registries in Europe, North America, and Oceania that provided data 
for the same period.
Data for prostate cancer are available for 4 999 267 men (table 3). 189 registries in 48 
countries contributed data for 1995–99, 241 registries in 57 countries provided data for 
2000–04, and 240 registries in 60 countries had data for 2005–09 (appendix pp 64–80). 
Among the 61 countries that provided data on prostate cancer, the range in age-standardised 
5-year net survival is very wide, from less than 40% to greater than 95%. For men diagnosed 
during 2005–09, survival was 90% or higher in Austria, Belgium, Brazil, Canada, Cyprus, 
Ecuador, Finland, France, Germany, Israel, Italy, Lithuania, Puerto Rico, and the USA (table 
4; appendix p 149). In the USA, where widespread prostate-specific antigen (PSA) testing 
was introduced around 1990, 5-year survival has been higher than 90% since 1995–99. 
Prostate cancer survival was 80–89% in 19 countries in Central and South America, Asia, 
Europe, and Oceania. In 18 other countries, survival ranged widely (50–79%), but in Libya 
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and Mongolia it was 40–41%. Striking and persistent increases in prostate cancer survival 
were seen in many countries between 1995–99 and 2005–09 (appendix p 160). Survival rose 
by 10–20% in 22 countries in Central and South America, Asia, and Europe; smaller 
increases (less than 10%) were seen in 15 countries.
Data for leukaemia in adults are available for 873 588 patients (table 3). 185 registries in 47 
countries provided data for 1995–99, 234 registries in 56 countries contributed data for 
2000–04, and 232 registries in 60 countries provided data for 2005–09 (appendix pp 64–80). 
For adults diagnosed with leukaemia during 2005–09, age-standardised 5-year net survival 
was 50–60% in 21 countries in North America, west Asia, Europe, and Oceania (table 4; 
appendix p 150). The estimate in Mauritius (57%) is based on 31 patients diagnosed in 
2005; it is not age-standardised and has a wide CI. Similarly, the estimate for Cuba (60%) is 
based on only 97 patients diagnosed during 1998–2006. 5-year net survival from adult 
leukaemia is generally much lower in the 15 participating Asian countries than in other 
regions of the world (appendix pp 163–73). With a few exceptions, survival seems to be low 
in east Asia (eg, from 19% in Japan to 23% in South Korea and Taiwan), high in west Asia 
(eg, from 33% in Turkey to 53% in Qatar), with a mixed picture in other Asian countries 
(eg, from 7% in Jordan to 40% in Indonesia). Survival estimates for adult leukaemia from 
Jordan, India, and Saudi Arabia might be less reliable for international comparison, but the 
overall pattern of leukaemia survival in Asia is still informative. Survival increases of 10–
16% for adult leukaemia were seen in China, Denmark, Germany, Iceland, Latvia, Sweden, 
and New Zealand. Smaller rises of 5–9% were noted in North America, Israel, Japan, South 
Korea, and ten European countries. In Malta, 5-year survival fell from 39% in 1995–99 
(based on 142 adults) to 19% for 2005–09 (128 adults; appendix p 161). This pattern is 
surprising, because data quality is very high (appendix pp 54–58) and survival trends for all 
solid tumours seem to be normal. Smaller declines were seen in several countries, such as 
Slovakia (from 41% to 37%) and Slovenia (from 44% to 38%).
Data for acute lymphoblastic leukaemia in children are available for 74 343 patients (table 
3). 173 registries in 42 countries contributed data for 1995–99, 215 registries in 50 countries 
provided data for 2000–04, and 213 registries in 53 countries provided data for 2005–09. In 
Romania (Cluj), data were only available for eight children and survival was not estimated. 
Of 53 countries, 32 provided data with 100% national population coverage. The geographic 
range in survival for acute lymphoblastic leukaemia in children was very wide. For patients 
diagnosed during 2005–09, age-standardised 5-year net survival was 90% or higher in 
Austria, Belgium, Canada, Germany, and Norway and 80–89% in 21 countries on various 
continents (table 4; appendix p 151). In many countries, however, 5-year net survival is still 
lower than 60%, even after adjustment for the very high background mortality in childhood. 
Survival was less than 50% in Indonesia, Mongolia, and Lesotho, although these estimates 
are based on very small numbers. The range of survival estimates for childhood acute 
lymphoblastic leukaemia in Central and South America (16 registries) and Asia (23 
registries) is much lower than the range in North America (48 registries), Europe (83 
registries), and Oceania (seven registries; appendix p 173). 5-year survival for childhood 
acute lymphoblastic leukaemia rose by 10% or more between 1995–99 and 2005–09 in 
Belarus, Belgium, Bulgaria, China, Colombia, Lithuania, Norway, Portugal, South Korea, 
Spain, Taiwan, and the UK. The estimate of 11% from China for 1995–99 is based on only 
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23 children, but the increase from 50% for 2000–04 to 61% for 2005–09 is more reliable. 
Increases in survival of up to 9% were seen in 16 other countries. 5-year survival in 
Argentina, Ecuador, and Slovakia was in the range 60–79%, with little or no change over 
time. Survival seemed to fall in Brazil (from 72% to 66%), Malaysia (from 77% to 69%), 
and Slovenia (from 83–86% in 1995–2004 to 76% for 2005–09). Survival trends could not 
be assessed in Africa.
Discussion
With CONCORD-2, we have initiated worldwide surveillance of trends in cancer survival. 
In the first CONCORD study,6 comparable estimates of cancer survival worldwide were 
provided: the study included 1·9 million patients diagnosed with breast, colorectal, or 
prostate cancer during 1990–94 and followed up to 1999 in 31 countries (panel). 
CONCORD-2 extends coverage to 25·7 million patients diagnosed with an invasive primary 
cancer during the 15-year period 1995–2009 in 67 countries. The ten index cancers represent 
about two-thirds of the overall cancer burden in both low-income and high-income 
countries.4 Individual patient data provided by 279 population-based cancer registries were 
prepared with standardised quality-control procedures and subjected to centralised analysis 
with the latest statistical methods.
The findings do not cover all countries, but they provide at least some population-based 
cancer survival estimates for 67 countries (26 of low or middle income) that are home to 
two-thirds of the world's population, including national data for 40 countries. The estimates 
are derived from analysis of raw data on the survival of individual cancer patients up to 5 
years after diagnosis. Until now, for comparison of global or continental survival, 
researchers generally needed to interpret scattered reports produced with diverse cancer 
defini tions, quality-control criteria, and survival estimators, for different calendar periods, 
and age-standardised to different sets of weights.46 More speculative comparisons have been 
based on modelling of mortality-incidence ratios, sometimes with data from neighbouring 
regions or countries,47 with all the attendant assumptions.48
Even after adjustment for the wide international variation in levels of mortality from other 
causes, and with due allowance for variation in quality of data, the global range in 5-year 
survival from ten cancers in adults and acute lymphoblastic leukaemia in children is very 
wide. For most cancers, survival in Africa, Asia, and Central and South America is lower, 
and the range in survival much wider, than in Europe, North America, and Oceania. The 
wider range is only partly attributable to the fact that not all cancer registries could provide 
data covering the 15 years from 1995 to 2009; for example, many of the Chinese registries 
contributed data for 2000–04 but not 2005–09. In North America and Oceania, population 
coverage was higher than 80% and the same registries generally provided data for the entire 
period 1995–2009 (figure 4; appendix pp 163–73): survival for most cancers was high on a 
global scale, with a fairly narrow range in estimates between registries.
5-year net survival from stomach cancer is generally in the range 25–30%, but it is very high 
(50–60%) in Japan, South Korea, and, to a lesser extent, Taiwan. High survival from 
stomach cancer in Japan,49 South Korea,50 and Taiwan51 is well known, and is likely to be 
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attributable to intensive diagnostic activity, early stage at diagnosis, and radical surgery. 
Survival varies according to sub-site, morphological type, and stage. Types of cancer with 
better prognosis might also be more common in Japan and South Korea, but the striking 
worldwide differences in survival suggest important lessons could be learnt from these 
countries about diagnosis and treatment.
5-year survival has risen for colon and rectal cancers in most developed countries and 
regions, including North America, Europe, Oceania, and parts of east Asia (South Korea and 
urban areas in China); increases in breast cancer survival have also been noted in these 
regions and in parts of Central and South America. These trends are likely to be attributable 
to earlier diagnosis, reduction in postoperative mortality,52 and more effective 
treatment.53,54 For rectal cancer, preoperative radiotherapy and total mesorectal excision 
reduce local recurrence and extend survival,55–57 which could account for improvements 
noted in Canada, Finland, the Netherlands, Norway, Sweden, and the USA, where survival 
was already high (55–60%) for patients diagnosed in 1995–99 and rose further for those 
diagnosed during 2005–09 (62–65%). These trends accord with those reported from the 
Netherlands,58 Scotland, the Nordic countries,59 and elsewhere in Europe.60
Liver and lung cancer remain lethal in both developing and developed countries, with 5-year 
survival generally lower than 20%, indicating that most patients are still diagnosed when 
they are inoperable. Primary prevention aimed at reducing tobacco and alcohol 
consumption, and prevention of chronic hepatitis, will be especially important for these 
cancers. The very low survival estimate for liver cancer in The Gambia (5%) is based on a 
sample of only 85 patients diagnosed during 1995–97 who were followed up for less than 5 
years, to the end of 1998; it is not age-standardised, but it is unlikely to be far wrong: 
patients in The Gambia tend to present with very advanced disease and cirrhosis and are not 
amenable to surgery.61 Overall completeness of registration is low, but the incidence of liver 
cancer is comparable with that of other west African populations.62 Data from the national 
cancer registry for The Gambia, set up in 1986 to support the IARC's Gambia Hepatitis 
Intervention Study,63 have been analysed previously,64 but more recent data were 
unavailable, so we cleaned and analysed them here alongside all other datasets, with 
permission from IARC.
The global range in 5-year survival from cervical cancer is very wide, from less than 40% to 
more than 70%. The overall decline in survival from 66% to 61% in France between 1995–
99 and 2000–04 was seen in all nine registries (appendix p 105). The decrease might be 
attributable to removal of less aggressive tumours by more intensive cervical screening for 
preinvasive lesions.65,66 Survival from cervical cancer in the Nordic countries was stable or 
rose slightly over the same period.67 By comparison, lower survival in low-income and 
middle-income countries is striking, since invasive cervical cancer is potentially curable 
with early detection by screening and appropriate surgery.68
5-year survival from ovarian cancer is generally in the range 30–40% in most parts of the 
world, but the overall range is much wider. Diversity in international survival might be 
attributable partly to variations in the proportion of tumours classified as type I (typically 
early-stage and slow-growing) and type II (typically late-stage and aggressive).69 
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Differences in stage at diagnosis and treatment are also likely to be important.70 Differential 
classification of borderline and invasive tumours might also contribute. Overall, however, 
worldwide survival trends show very little improvement between 1995–99 and 2005–09 
(appendix p 158). This finding accords with the absence of improvement reported from 
many developed countries.7,9
Striking increases in 5-year survival from prostate cancer have occurred in many countries, 
but global trends varied widely. Examples include three northern European countries, all 
with nationwide cancer registration. 5-year survival in Lithuania jumped from 52% for men 
diagnosed during 1995–99 to 92% for those diagnosed during 2005–09. The rise in Latvia 
was from 52% to 74%: access to health care in these countries has improved, and 
opportunistic PSA screening began in 2000.71 In Denmark, survival rose from 46% to 77% 
over the same period, having been stable at 40% throughout the period 1982–94,72 during 
which time survival increased rapidly in the other four Nordic countries.73 The Danish 
Urology Society advised against PSA testing in asymptomatic men in the early 1990s,74 but 
this advice is now followed less widely. By contrast, survival in North America and Oceania 
was already very high in the late 1990s, and increases since then have been much smaller. In 
Africa, we were unable to assess a trend.
Survival from both adult and childhood leukaemia in east Asia is surprisingly low. The low 
survival for adult leukaemia in Japan, South Korea, and Taiwan is especially surprising, 
because survival from solid tumours is generally high. Could ethnic or genetic factors play a 
part? This possibility has been suggested in a recent comparison of survival from chronic 
lymphocytic leukaemia between Taiwan and the USA.75 Leukaemia survival is also low in 
China, but haematological malignant diseases have received low priority in cancer control 
there, with limited access to health insurance and chemotherapy,76 and medical resources in 
rural areas are poor.77
The global range in 5-year survival from acute lymphoblastic leukaemia in children is very 
wide, from less than 60% in several countries to 90% or higher in Austria, Belgium, Canada, 
Germany, and Norway. This finding confirms that major deficiencies are present in the 
management of what is now a largely curable disease.78 Failure to start or complete 
treatment, usually for financial reasons, is an important contributor to the survival deficit in 
developing countries.79
Standardised quality controls were applied systematically to all datasets. Detailed 
discussions were held with every registry to identify and correct any errors or artifacts in the 
data. Many registries resubmitted their data after correction, which greatly improved data 
quality and comparability. The overall proportion of eligible tumours excluded from 
analysis was low (3·6%), but it was much higher for some registries and varied widely 
between cancers. For some populations, mostly in low-income and middle-income countries, 
these exclusions will have biased survival estimates upwards. Thus, the proportion of cancer 
registrations from a death certificate only was typically higher in countries where survival is 
low. This leads to exclusion from analysis of a group of patients who tend to have low 
survival,80 leading to overestimation of the level of survival in that population. This bias 
would tend to reduce international differences.
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Various indications suggest that the data submitted by some registries were not exhaustive, 
either because there were fewer cancer patients than expected or because the full range of 
haemopoietic malignant diseases was not represented in some of the leukaemia datasets. The 
smaller number of cancer registrations in Poland for 1995–99 reflects a national strike of 
doctors in 1997, but we have little reason to suppose this type of incompleteness would bias 
survival estimates.
Pathological confirmation of diagnosis was available for more than 90% of cancers included 
in the analyses (98·5% for childhood acute lymphoblastic leukaemia), and less than 4% of 
malignant diseases were assigned to a non-specific morphology code. Nevertheless, 
considerable variation was noted, and pathological evidence was much less complete for 
some populations in low-income and middle-income countries (table 2; appendix pp 3–63).
Several registries reported high proportions of intestinal-type adenocarcinoma in the colon 
and rectum: this morphological type was originally described (in 1965) for carcinoma of the 
stomach81 and is included in ICD-O-3 (M8144). A similar issue arose with 
cholangiocarcinoma (M8160) coded as arising in the liver (ICD-O-3 site code C22.0) rather 
than the intrahepatic bile duct (C22.1). If we were told that pathologists frequently use these 
terms for malignant disease of the large bowel or liver, respectively, we included the 
patients in our analyses.
The distribution of cancers within an organ by anatomic sub-site or morphological type can 
differ between populations, so any differences in survival by sub-site or morphological 
features could affect comparisons of overall survival. We will address the effect on survival 
of these differences in biology with more detailed analyses, particularly for cancers of the 
stomach, lung, and ovary. Leukaemia comprises a broad and heterogeneous group of 
diseases. We excluded chronic myeloid leukaemia; survival for other major groups will be 
investigated in more detail.
Premalignant and small malignant lesions can be detected more frequently in countries with 
mass screening programmes or intensive early diagnostic activity, particularly for cancers of 
the breast, cervix, colon, rectum, and prostate. Differences in tumour stage at diagnosis can 
contribute to international variations in overall survival between low-income countries.8 
Wide differences in tumour stage at diagnosis and stage-specific survival have also been 
recorded among high-income countries.59,70,82–84 High-resolution studies of tumour stage at 
diagnosis, treatment, and adherence to guidelines have helped account for international 
differences in survival.55,85–87 The comparability of data gathered routinely on cancer stage 
remains poor in developed countries,88 even though the TNM classification89 has been 
available for more than 60 years. We will examine in more detail the extent to which 
available data on tumour stage can explain the very wide global differences in survival 
reported by us here.
We imputed the day of diagnosis in data from registries that only record (or were only 
allowed to submit) the month and year of diagnosis. A few of those registries also submitted 
survival time in days; our imputation achieved similar results. The effect on short-term 
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survival of minor variations in the date of diagnosis is generally small90 and cannot account 
for the very wide international differences in 5-year survival.91
Loss to follow-up of cancer patients in registries using active follow-up varied widely, but 
most registries also used several passive follow-up techniques. Differences between the 
databases used for passive follow-up can affect survival estimates.92,93 When information 
for all deaths is incomplete or inaccessible from administrative systems, active follow-up by 
the registry augments completeness of ascertainment of vital status, particularly in low-
income and middle-income countries.94 Some registries did not have the resources to follow 
up all their patients for vital status. Others could not provide follow-up data for at least 5 
years after diagnosis for all their patients; for those registries, we have presented survival at 
3 or 4 years if possible.
If age-specific (and thus age-standardised) survival estimates could not be produced, non-
standardised estimates for all ages combined were presented. In some analyses, data had to 
be pooled across two or three calendar periods, restricting presentation of survival trends. 
For some countries or regions with very small populations, no survival estimate could be 
made at all for less common cancers, because very few patients were available for analysis.
We used a rigorously enforced protocol, with centralised data evaluation and analysis to 
enhance comparability, but international survival comparisons should still be interpreted 
with caution. Data quality varies widely:95,96 we provided detailed indices of data quality at 
country and registry level (table 2; appendix pp 3–63), which should be taken into account. 
Not all countries could provide data for 2005–09. Also, the range in size between the 
smallest and largest populations included in this report is greater than 1000-fold, both for 
registries with national coverage (eg, Gibraltar includes 29 000 people and the UK covers 
61·8 million people) and those with regional coverage (eg, Nunavut in Canada represents 33 
000 people whereas California in the USA includes 37·0 million people). These differences 
are reflected in the numbers of patients and the width of CIs around survival estimates. 
However, lack of precision because of small numbers does not necessarily imply that the 
survival estimates are incorrect or unreliable: high quality and completeness of data and 
follow-up can be easier to achieve in small or island populations than in large urban 
populations.
For robust international comparison of cancer survival, differences and trends in background 
mortality according to age, sex, region, and ethnic origin must be taken into account. In the 
populations covered by these data, the range in background mortality was very wide, 
measured by life expectancy at birth (46–87 years in females and 45–81 years in males), and 
by the change in life expectancy between 1995 and 2009 (appendix p 175), and in other 
metrics such as the probability of death in middle age (data not shown). We created more 
than 6500 complete life tables of background mortality to capture these differences.
For children with cancer, usual practice is to present the observed probability of survival, 
including all causes of death,97 rather than net survival, because mortality from other causes 
is typically very low, at least in developed countries. Here, however, we have estimated net 
survival for children with acute lymphoblastic leukaemia because, among the 53 countries 
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for which data could be analysed, mortality from other causes in childhood varied very 
widely. In 2002, infant mortality ranged from less than one death per 1000 livebirths to more 
than 120 deaths per 1000 livebirths (in some African populations); under-5 mortality ranged 
from less than one death per 1000 livebirths to more than 200 deaths per 1000 livebirths; 
and the overall probability of death before age 15 years ranged from one death per 1000 
livebirths to more than 250 per 1000 livebirths (data not shown). For a worldwide 
comparison of survival from childhood acute lymphoblastic leukaemia, it seemed especially 
important to eliminate the effect of this wide variation in background mortality between 
countries and over time.
Net survival was age-standardised in most estimates for both adults and children. Age 
standardisation minimises the risk of reporting international differences or trends in cancer 
survival that are attributable solely to international differences or changes over time in the 
age distribution of cancer patients.42
We included both first and higher order cancers in our analyses. The effect of multiple 
primary cancers on overall survival is typically only 1–2%,98 but the proportion of such 
cancers in a given population is affected by the set of rules used to define them99 and by the 
longevity of the registry.100 Some participating registries began operation in the 1950s 
whereas others only started after 2000. In long-established registries, 10% or more of 
patients might be registered with more than one cancer.101 This proportion is lower in newer 
registries, because a second cancer will typically be registered as the patient's first. 
Restriction to first primaries can also affect international comparison of survival trends, 
because the number of long-term survivors at high risk of another cancer is increasing, 
particularly in high-income countries.102 Exclusion of second cancers would, therefore, tend 
to bias international survival comparisons in favour of wealthier countries.103 The rules for 
defining multiple primary cancers differ between North America and the rest of the 
world,24,25 but in a novel step, data from registries in North America were first converted to 
IACR definitions used elsewhere, before being submitted for analysis. This alteration will 
have minimised any effect on international survival comparisons presented here.
To maintain the breadth of global surveillance of survival, we retained some datasets that 
seemed less suitable for international comparison than all other estimates, but we flagged 
these survival estimates to inform interpretation. The number of flagged estimates is larger 
than in the first CONCORD study6 because more registries are from low-income countries 
and the data cover a much longer period. Residual errors and artifacts in data undoubtedly 
exist, but they are unlikely to account for global patterns and trends in cancer survival.
We used an unbiased estimator of net survival.104 To our knowledge, this is the first time 
this estimator has been used for an international comparison. We used the period approach33 
to estimate survival up to 5 years after diagnosis for patients diagnosed during 2005–09 
(appendix p 174). This approach offers reliable prediction of the eventual survival of 
recently diagnosed patients who have not all been followed up for 5 years.105
A small part of the global range in survival could be attributable to differences in the 
intensity of diagnostic activity. The introduction of new diagnostic techniques in wealthier 
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countries, such as PSA testing for prostate cancer, has led to more patients being diagnosed 
at an early stage of disease, typically with a good prognosis, thus inflating both incidence 
and survival. We were not able to use the proportion of in situ cancers for international 
comparison of the intensity of diagnostic activity for cancers of the colon, rectum, breast, 
cervix, or prostate. Some registries do not collect data for in situ tumours, whereas some 
registries that do collect this information did not include these data in their submissions. In 
poorer countries, by contrast, many patients still die undiagnosed or untreated.68
For some cancers, both incidence and survival in countries with the most intensive 
diagnostic activity could be inflated slightly by overdiagnosis, but the effect on the global 
range of survival estimates is probably small. Equally, in the poorest countries, under-
registration of cancer patients with the worst prognosis might lead to underestimation of 
incidence and overestimation of survival. Even though some survival estimates in low-
income and middle-income countries might be too high for this reason, it is striking that for 
cancers of the colon, rectum, lung, and breast, and particularly for leukaemia in adults and 
children, the range of estimates in Africa and Central and South America for patients 
diagnosed during 2005–09 is still much lower than in North America and Oceania during 
1995–99, 10 years earlier (figure 4; appendix pp 163–73). As reported elsewhere,68 these 
patterns strongly suggest inadequate access to early diagnosis and optimum treatment.
National health-care systems must manage all cancer patients, however they are diagnosed, 
even if some patients might not have been diagnosed before widespread adoption of new 
diagnostic techniques or screening programmes. In a given country, incidence and survival 
estimates reflect current approaches to prevention, diagnosis, and treatment.6 Coherent 
assessment of preventive and health-care strategies, therefore, requires that all cancer 
patients are included, no matter how they are diagnosed, in both incidence and survival 
estimates. Projections of the future burden of cancer106 are based on the same cancer 
incidence data.
Some cancer registries followed up their patients for the first time so they could participate 
in CONCORD-2. Other registries, not all of them in low-income countries, were prevented 
from participating by scant resources either to follow up registered patients for vital status or 
to prepare data for submission. This deficit underscores the continued fragility, low 
coverage, and scarcity of resources for cancer registries.4,107,108 In many countries, even the 
basic infrastructure of a civil registration system and vital statistics is deficient.109 This 
absence is especially severe in Africa, where several participating countries have also been 
subject to civil or military conflict within the past 10–15 years and where, with few 
exceptions, assessment of recent survival trends from available data was almost impossible.
Cancer registries are crucial to our understanding of the global cancer burden,107 and they 
need to be funded and equipped to gather, analyse, and publish incidence and survival data 
at national or regional level. Worldwide monitoring of cancer incidence has been done since 
the 1960s, with centralised data collection and standardised methods in Cancer Incidence in 
Five Continents.16 IARC's Global Initiative for Cancer Registry Development is an 
important stimulus to promote high-quality data collection and cancer registration in low-
income and middle-income countries.108
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Both WHO3 and the UN110 have recognised cancer as a worldwide public health issue of 
growing concern. However, if cancer registration is to develop further in support of the 25 × 
25 goals and in the evaluation of clinical care,111 WHO and the UN will need to address the 
growing legal and procedural difficulties in obtaining primary health data and in accessing 
them for research. For example, legislation now at the final stage of discussion in the 
European Union would make cancer registration and most forms of public health research 
either impossible or illegal in 28 European countries.112,113
The CONCORD programme at the London School of Hygiene & Tropical Medicine 
(LSHTM) represents the establishment of worldwide surveillance of cancer survival by 
centralised quality control and analysis of population-based registry data, as a comparative 
metric of the effectiveness of health systems. It will provide part of the evidence base for 
global policy on cancer control and should contribute to the overarching goal of the World 
Cancer Declaration 201314 and, more broadly, to the “revolution in metrics for global 
health”.114
At a national level, cancer outcomes are affected by the organisation and funding of access 
to health services.115 Improvements in cancer survival have been reported after major 
political and economic changes in Estonia,116 Lithuania,117 and Germany.118 In turn, low 
survival has affected the development of cancer strategy in countries such as Algeria,119 
Brazil,120,121 Mexico,122 China, India, and Russia,123 and in many wealthier countries.4
Some of the conclusions drawn from these analyses are similar to those for patients 
diagnosed 20–25 years ago.6 The findings of this study can be used to assess the extent to 
which investment in health-care systems is improving their effectiveness. We will examine 
survival trends and differentials in relation to health economic indicators to assess why 
improvements in survival are so slow and unequal.
Most of the wide global range in cancer survival is probably attributable to inequity in 
access to optimum diagnostic and treatment services,6 both in rich124–126 and poor127,128 
countries. Availability of linear accelerators varies more than ten-fold worldwide, from one 
machine per 500 000 population to less than one per five million people, and more than 30 
countries in Africa and Asia have no radiotherapy service at all.129 Cancer survival in 
Europe has been associated with gross national product, total national expenditure on health 
and investment in health technology (eg, CT scanners, radiotherapy units),130 and with 
suboptimum allocation of available resources.86 The global economic cost of cancer from 
premature death and lost productivity was estimated at US$895 billion in 2008, excluding 
direct treatment costs estimated at $300 billion.131 Even in wealthy countries, the rapidly 
growing costs of cancer treatment have raised concerns about the growing use of tests, 
imaging, and treatments that are expensive but have marginal value.132 At the same time, 
closing the rich–poor divide in access to cancer treatment has been described as “an equity 
imperative”.133,134 The findings reported here confirm the global divide in outcomes.
The first international study of cancer survival was published 50 years ago.5 In the same 
year, Alexander Langmuir, founder of the US Centers for Disease Control and Prevention's 
epidemic intelligence service, commented on national outbreaks of infectious disease: “good 
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surveillance does not necessarily ensure the making of the right decisions, but it reduces the 
chances of wrong ones”.135 His view applies today to non-communicable diseases such as 
cancer, for which long-term surveillance of incidence, mortality, and survival is increasingly 
important. Survival is a key metric of overall progress in cancer control.4 Continuous 
worldwide surveillance of cancer survival should become both an indispensable source of 
information for cancer patients and researchers and a stimulus for politicians to improve 
health policy and health-care systems.
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Africa—Algeria: S Bouzbid (Registre du Cancer d'Annaba); M Hamdi-Chérif*, Z Zaidi 
(Registre du Cancer de Sétif); Gambia: E Bah, R Swaminathan (National Cancer Registry); 
Lesotho: SH Nortje, CD Stefan (Children's Haematology Oncology Clinics - Lesotho); 
Libya: MM El Mistiri (Benghazi Cancer Registry); Mali: S Bayo, B Malle (Kankou Moussa 
University); Mauritius: SS Manraj, R Sewpaul-Sungkur (Mauritius Cancer Registry); 
Nigeria: A Fabowale, OJ Ogunbiyi* (Ibadan Cancer Registry); South Africa: D Bradshaw, 
NIM Somdyala (Eastern Cape Province Cancer Registry); Sudan: M Abdel-Rahman 
(University of Khartoum); Tunisia: L Jaidane, M Mokni (Registre du Cancer du Centre 
Tunisien).
America (Central and South)—Argentina: I Kumcher, F Moreno (National Childhood 
Cancer Registry); MS González, E Laura (Registro Regional de Tumores del Sur de la 
Provincia de Buenos Aires); FV Pugh, ME Torrent (Chubut Cancer Registry); B Carballo 
Quintero, R Fita (Registro de Tumores de Córdoba); D Garcilazo, PL Giacciani (Entre Rios 
Cancer Registry); MC Diumenjo, WD Laspada (Registro Provincial de Tumores de 
Mendoza); MA Green, MF Lanza (Registro de Cáncer de Santa Fe); SG Ibañez (Tierra del 
Fuego Cancer Registry); Brazil: CA Lima, E Lobo (Registro de Câncer de Base 
Populacional de Aracaju); C Daniel, C Scandiuzzi (Cancer Registry of Distrito Federal); 
PCF De Souza (Registro de Câncer de Base Populacional de Cuiabá); K Del Pino, C Laporte 
(Registro de Curitiba); MP Curado, JC de Oliveira (Registro de Goiânia); CLA Veneziano, 
DB Veneziano (Registro de Câncer de Base Populacional de Jahu); TS Alexandre, AS 
Verdugo (Registro de Câncer de São Paulo); S Koifman†* (National School of Public 
Health); G Azevedo e Silva* (University of Rio de Janeiro); Chile: JC Galaz, JA Moya 
(Registro Poblacional de Cáncer Region de Antofagasta); DA Herrmann, AM Jofre 
(Registro Poblacional Region de Los Rios); Colombia: CJ Uribe (Registro Poblacional de 
Cáncer Area Metropolitana de Bucaramanga); LE Bravo (Cali Cancer Registry); G Lopez 
Guarnizo (Registro Poblacional de Cáncer Manizales); DM Jurado, MC Yepes (Registro 
Poblacional de Cáncer del Municipio de Pasto); Cuba: YH Galán, P Torres (Registro 
Nacional de Cáncer de Cuba); Ecuador: F Martínez-Reyes (Cuenca Tumor Registry); L 
Jaramillo, R Quinto (Guayaquil Cancer Registry); P Cueva, J Yépez (Quito Cancer 
Registry); Puerto Rico: CR Torres-Cintrón, G Tortolero-Luna (Puerto Rico Central Cancer 
Registry); Uruguay: R Alonso, E Barrios (Registro Nacional de Cáncer).
America (North)—Canada: C Russell, L Shack (Alberta Cancer Registry); AJ Coldman, RR 
Woods (British Columbia Cancer Registry); G Noonan, D Turner* (Manitoba Cancer 
Registry); E Kumar, B Zhang (New Brunswick Provincial Cancer Registry); FR McCrate, S 
Ryan (Newfoundland Cancer Registry); H Hannah (Northwest Territories Cancer Registry); 
RAD Dewar, M MacIntyre (Nova Scotia Surveillance and Epidemiology Unit); A Lalany, 
M Ruta (Nunavut Department of Health and Social Services); L Marrett, DE Nishri* 
(Ontario Cancer Registry); KA Vriends (Prince Edward Island Cancer Registry); C 
Bertrand, R Louchini (Registre Québécois du Cancer); KI Robb, H Stuart-Panko 
(Saskatchewan Cancer Registry); S Demers, S Wright (Yukon Government); USA: J 
George, X Shen (Alabama Statewide Cancer Registry); JT Brockhouse, DK O'Brien (Alaska 
Cancer Registry); L Almon, JL Young* (Metropolitan Atlanta Registry); J Bates (California 
State Cancer Registry); R Rycroft (Colorado Central Cancer Registry); L Mueller, C Phillips 
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(Connecticut Tumor Registry); H Ryan, J Walrath (Delaware Cancer Registry); A Schwartz, 
F Vigneau (Metropolitan Detroit Cancer Surveillance System); JA MacKinnon, B Wohler 
(Florida Cancer Data System); R Bayakly, KC Ward (Georgia Comprehensive Cancer 
Registry); K Davidson-Allen, S Glaser (Greater Bay Area Cancer Registry); D West (Cancer 
Registry of Greater California); MD Green, BY Hernandez (Hawaii Tumor Registry); CJ 
Johnson (Cancer Data Registry of Idaho); CF Lynch, KM McKeen (State Health Registry of 
Iowa); B Huang, TC Tucker* (Kentucky Cancer Registry); D Deapen, L Liu (Los Angeles 
Cancer Surveillance Program); MC Hsieh, XC Wu (Louisiana Tumor Registry); K Stern 
(Maryland Cancer Registry); ST Gershman, RC Knowlton (Massachusetts Cancer Registry); 
G Copeland, G Spivak (Michigan State Cancer Surveillance Program); DB Rogers 
(Mississippi Cancer Registry); D Lemons, LL Williamson (Montana Central Tumor 
Registry); M Hood, H Jerry (Nebraska Cancer Registry); GM Hosain, JR Rees (New 
Hampshire State Cancer Registry); KS Pawlish, A Stroup (New Jersey State Cancer 
Registry); C Key, C Wiggins (New Mexico Tumor Registry); AR Kahn, MJ Schymura 
(New York State Cancer Registry); G Leung, C Rao (North Carolina Central Cancer 
Registry); L Giljahn, B Warther (Ohio Cancer Incidence Surveillance System); A Pate 
(Oklahoma Central Cancer Registry); M Patil, DK Shipley (Oregon State Cancer Registry); 
M Esterly, RD Otto (Pennsylvania Cancer Registry); JP Fulton, DL Rousseau (Rhode Island 
Cancer Registry); TA Janes, SM Schwartz (Seattle Cancer Surveillance System); SW 
Bolick, DM Hurley (South Carolina Central Cancer Registry); RA Tenney, MA Whiteside 
(Tennessee Cancer Registry); A Hakenewerth, MA Williams (Texas Cancer Registry); K 
Herget, C Sweeney (Utah Cancer Registry); J Martin, S Wang (Virginia Cancer Registry); 
MG Harrelson, MB Keitheri Cheteri (Washington State Cancer Registry); AG Hudson 
(West Virginia Cancer Registry); R Borchers, L Stephenson (Wisconsin Department of 
Health Services); JR Espinoza (Wyoming Cancer Surveillance Program); HK Weir* 
(Centers for Disease Control and Prevention); BK Edwards* (National Cancer Institute).
Asia—China: N Wang, L Yang (Beijing Cancer Registry); JS Chen (Changle City Cancer 
Registry); GH Song (Cixian Cancer Registry); XP Gu (Dafeng County Center for Disease 
Control and Prevention); P Zhang (Dalian Centers for Disease Prevention and Control); HM 
Ge (Donghai County Center for Disease Prevention and Control); DL Zhao (Feicheng 
County); JH Zhang (Ganyu Center for Disease Prevention and Control); FD Zhu (Guanyun 
Cancer Registry); JG Tang (Haimen Cancer Registry); Y Shen (Haining City Cancer 
Registry); J Wang (Jianhu Cancer Registry); QL Li (Jiashan County Cancer Registry); SP 
Yang (Jintan Cancer Registry); JM Dong, WW Li (Lianyungang Center for Disease 
Prevention and Control); LP Cheng (Henan Province Central Cancer Registry); JG Chen 
(Qidong County Cancer Registry); QH Huang (Sihui Cancer Registry); SQ Huang (Taixing 
Cancer Registry); GP Guo (Cancer Institute of Yangzhong City); K Wei (Zhongshan City 
Cancer Registry); WQ Chen*, H Zeng (National Central Cancer Registry China); Cyprus: 
AV Demetriou, P Pavlou (Cyprus Cancer Registry); Hong Kong: WK Mang, KC Ngan 
(Hong Kong Cancer Registry); India: R Swaminathan (Chennai Cancer Registry); AC 
Kataki, M Krishnatreya (Guwahati Cancer Registry); PA Jayalekshmi, P Sebastian 
(Karunagappally Cancer Registry); SD Sapkota, Y Verma (Population Based Cancer 
Registry, Sikkim); A Nandakumar* (National Centre for Disease Informatics and Research; 
National Cancer Registry Programme); Indonesia: E Suzanna (Jakarta Cancer Registry); 
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Israel: L Keinan-Boker, BG Silverman (Israel National Cancer Registry); Japan: H Ito 
(Aichi Cancer Registry); M Hattori (Fukui Cancer Registry); H Sugiyama, M Utada 
(Hiroshima Prefecture Cancer Registry); K Katayama, S Natsui (Kanagawa Cancer 
Registry); T Matsuda*, Y Nishino (Miyagi Prefectural Cancer Registry); T Koike (Niigata 
Prefecture Cancer Registry); A Ioka, K Nakata (Osaka Cancer Registry); K Kosa (Saga 
Prefectural Cancer Registry); I Oki (Tochigi Prefectural Cancer Registry); A Shibata 
(Yamagata Cancer Registry); Jordan: O Nimri (Jordan National Cancer Registry); Malaysia: 
A Ab Manan, N Bhoo Pathy (Penang Cancer Registry); Mongolia: C Ochir, S Tuvshingerel 
(Cancer Registry of Mongolia); Qatar: AM Al Khater, MM El Mistiri (Qatar Cancer 
Registry); Saudi Arabia: H Al-Eid (Saudi National Cancer Registry); South Korea: KW 
Jung, YJ Won (Korea Central Cancer Registry); S Park (University of Yonsei); Taiwan: CJ 
Chiang, MS Lai (Taiwan Cancer Registry); Thailand: K Suwanrungruang, S Wiangnon 
(Khon Kaen Provincial Registry); K Daoprasert, D Pongnikorn (Lampang Cancer Registry); 
SL Geater, H Sriplung (Songkhla Cancer Registry); Turkey: S Eser, CI Yakut (Izmir Cancer 
Registry).
Europe—Austria: M Hackl, N Zielonke (Austrian National Cancer Registry); H Mühlböck, 
W Oberaigner (Tyrol Cancer Registry); M Piñeros* (IAEA, PACT Programme); Belarus: 
AA Zborovskaya (Belarus Childhood Cancer Subregistry); Belgium: K Henau, L Van 
Eycken (Belgian Cancer Registry); Bulgaria: N Dimitrova, Z Valerianova (Bulgarian 
National Cancer Registry); Croatia: M Šekerija, A Znaor (Croatian National Cancer 
Registry); Czech Republic: M Zvolský (Czech National Cancer Registry); Denmark: G 
Engholm, H Storm* (Danish Cancer Society); Estonia: T Aareleid, M Mägi (Estonian 
Cancer Registry); Finland: N Malila, K Seppä (Cancer Society of Finland); France: M 
Velten (Bas-Rhin General Cancer Registry); E Cornet, X Troussard (Registre Régional des 
Hémopathies Malignes de Basse Normandie); AM Bouvier, J Faivre (Burgundy Digestive 
Cancer Registry); AV Guizard (Calvados General Cancer Registry); V Bouvier, G Launoy 
(Calvados Digestive Cancer Registry); P Arveux (Côte-d'Or Gynaecologic Cancer 
Registry); M Maynadié, M Mounier (Côte-d'Or Haematopoietic Malignancies Registry); AS 
Woronoff (Doubs and Belfort Territory General Cancer Registry); M Daoulas (Finistère 
Cancer Registry); J Clavel (National Registry of Childhood Haematopoietic Malignancies); 
S Le Guyader-Peyrou, A Monnereau (Gironde Haematopoietic Malignancies Registry); B 
Trétarre (Hérault General Cancer Registry); M Colonna (Isère General Cancer Registry); S 
Delacour-Billon, F Molinié (Loire-Atlantique-Vendée Cancer Registry); S Bara, D Degré 
(Manche General Cancer Registry); O Ganry, B Lapôtre-Ledoux (Somme General Cancer 
Registry); P Grosclaude (Tarn General Cancer Registry); JM Lutz* (Grenoble); A Belot, J 
Estève (Hospices Civils de Lyon); D Forman* (International Agency for Research on 
Cancer); F Sassi (Organisation for Economic Co-operation and Development); Germany: R 
Stabenow (Common Cancer Registry of the Federal States); A Eberle (Bremen Cancer 
Registry); A Nennecke (Hamburg Cancer Registry); J Kieschke, E Sirri (Epidemiological 
Cancer Registry of Lower Saxony); H Kajueter (North Rhine Westphalia Cancer Registry); 
K Emrich, SR Zeissig (Rhineland Palatinate Cancer Registry); B Holleczek (Saarland 
Cancer Registry); N Eisemann, A Katalinic (Schleswig-Holstein Cancer Registry); H 
Brenner (German Cancer Research Center); Gibraltar: RA Asquez, V Kumar (Gibraltar 
Cancer Registry); Iceland: EJ Ólafsdóttir, L Tryggvadóttir (Icelandic Cancer Registry); 
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Ireland: H Comber, PM Walsh (National Cancer Registry); H Sundseth* (European Institute 
of Women's Health); Italy: T Dal Cappello, G Mazzoleni (Registro Tumori Alto Adige); A 
Giacomin (Registro Tumori Biella); M Castaing, S Sciacca (Integrated Cancer Registry of 
Catania-Messina-Siracusa-Enna); A Sutera (Registro Tumori Catanzaro); M Corti, G Gola 
(Registro Tumori della Provincia di Como); S Ferretti (Registro Tumori della Provincia di 
Ferrara); D Serraino, A Zucchetto (Registro Tumori del Friuli Venezia Giulia); R Lillini, M 
Vercelli (Registro Tumori Regione Liguria); S Busco, F Pannozzo (Registro Tumori della 
Provincia di Latina); S Vitarelli (Registro Tumori della Provincia di Macerata); P Ricci 
(Registro Tumori Mantova); V Pascucci (Registro Tumori Marche Childhood); M 
Autelitano (Registro Tumori Milano); C Cirilli, M Federico (Registro Tumori della 
Provincia di Modena); M Fusco, MF Vitale (Registro Tumori della ASL Napoli 3 sud); M 
Usala (Nuoro Cancer Registry); R Cusimano, F Vitale (Registro Tumori Palermo); M 
Michiara, P Sgargi (Registro Tumori della Provincia di Parma); C Sacerdote (Piedmont 
Childhood Cancer Registry); R Tumino (Registro Tumori della Provincia di Ragusa); L 
Mangone (Registro Tumori Reggio Emilia); F Falcini (Registro Tumori della Romagna); L 
Cremone (Registro Tumori Salerno); M Budroni, R Cesaraccio (Registro Tumori della 
Provincia di Sassari); A Madeddu, F Tisano (Registro Tumori Siracusa); S Maspero, R 
Tessandori (Registro Tumori della Provincia di Sondrio); G Candela, T Scuderi (Registro 
Tumori Trapani); S Piffer (Registro Tumori Trento); S Rosso, R Zanetti (Registro Tumori 
Piemonte Città di Torino); A Caldarella, E Crocetti (Registro Tumori della Regione 
Toscana); F La Rosa, F Stracci (Registro Tumori Umbro di Popolazione); P Contiero, G 
Tagliabue (Registro Tumori Lombardia, Provincia di Varese); P Zambon (Registro Tumori 
Veneto); P Baili, F Berrino*, G Gatta, M Sant* (National Cancer Institute); R Capocaccia*, 
R De Angelis, A Verdecchia* (National Centre for Epidemiology); Latvia: E Liepina, A 
Maurina (Latvian Cancer Registry); Lithuania: G Smailyte (Lithuanian Cancer Registry); 
Malta: D Agius, N Calleja (Malta National Cancer Registry); Netherlands: S Siesling 
(Comprehensive Cancer Centre of the Netherlands); Norway: S Larønningen, B Møller (The 
Cancer Registry of Norway); Poland: A Dyzmann-Sroka, M Trojanowski (Greater Poland 
Cancer Registry); S Góźdż, R Mężyk (Cancer Registry of Kielce); M Grądalska-Lampart, 
AU Radziszewska (Podkarpackie Cancer Registry); J Didkowska, U Wojciechowska 
(National Cancer Registry); J Błaszczyk, K Kępska (Lower Silesian Cancer Registry); M 
Bielska-Lasota (National Institute of Public Health); Portugal: G Forjaz, RA Rego (Registo 
Oncológico Regional dos Açores); J Bastos (Registo Oncológico Regional do Centro); L 
Antunes, MJ Bento (Registo Oncológico Regional do Norte); AM da Costa Miranda, A 
Mayer-da-Silva (Registo Oncólogico Regional do Sul); Romania: D Coza, AI Todescu 
(Cancer Institute I. Chiricuta); Russia: A Krasilnikov, M Valkov (Arkhangelsk Regional 
Cancer Registry); Slovakia: J Adamcik, C Safaei Diba (National Cancer Registry of 
Slovakia); Slovenia: M Primic Žakelj, T Žagar (Cancer Registry of Republic of Slovenia); J 
Stare (University of Ljubljana); Spain: E Almar, A Mateos (Registro de Cáncer de 
Albacete); MV Argüelles, JR Quirós (Registro de Tumores del Principado de Asturias); J 
Bidaurrazaga, N Larrañaga (Basque Country Cancer Registry); JM Díaz García, AI Marcos 
(Registro de Cáncer de Cuenca); R Marcos-Gragera, ML Vilardell Gil (Registre de Càncer 
de Girona); E Molina, MJ Sánchez (Registro de Cáncer de Granada); M Ramos Montserrat 
(Mallorca Cancer Registry); MD Chirlaque, C Navarro (Murcia Cancer Registry); E 
Ardanaz (Registro de Cáncer de Navarra); S Felipe Garcia, R Peris-Bonet (Registro 
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Nacional de Tumores Infantiles); J Galceran (Tarragona Cancer Registry); Sweden: S Khan, 
M Lambe (Swedish Cancer Registry); Switzerland: B Camey (Registre Fribourgeois des 
Tumeurs); C Bouchardy, M Usel (Geneva Cancer Registry); SM Ess, C Hermann (Cancer 
Registry Grisons and Glarus; Cancer Registry of St Gallen-Appenzell); FG Levi, M 
Maspoli-Conconi (Registre Neuchâtelois des Tumeurs); CE Kuehni, VR Mitter (Swiss 
Childhood Cancer Registry); A Bordoni, A Spitale (Registro Tumori Cantone Ticino); A 
Chiolero, I Konzelmann (Registre Valaisan des Tumeurs); SI Dehler, RI Laue (Krebsregister 
Kanton Zürich); United Kingdom: D Meechan, J Poole (East Midlands); D Greenberg, J 
Rashbass (East of England); E Davies, K Linklater (London); E Morris (North East); T 
Moran (North West); F Bannon, A Gavin (Northern Ireland Cancer Registry); RJ Black, DH 
Brewster (Scottish Cancer Registry); M Roche (South East); S McPhail, J Verne (South 
West); M Murphy, C Stiller* (National Registry of Childhood Tumours); DW Huws, C 
White (Welsh Cancer Intelligence & Surveillance Unit); G Lawrence (West Midlands); C 
Brook, J Wilkinson (Yorkshire and the Humber); P Finan (Leeds General Infirmary); JV 
Ahn, C Allemani*, A Bonaventure, H Carreira, MP Coleman*, R Harewood, B Rachet*, N 
Sanz, D Spika, XS Wang (London School of Hygiene & Tropical Medicine); R Stephens* 
(National Cancer Research Institute, London); J Butler (Royal Marsden Hospital); M Peake 
(University of Leicester).
Oceania—Australia: E Chalker, L Newman (Australian Capital Territory Cancer Registry); 
D Baker, MJ Soeberg (NSW Central Cancer Registry); C Scott (Queensland Cancer 
Registry); BC Stokes, A Venn (Tasmanian Cancer Registry); H Farrugia, GG Giles 
(Victorian Cancer Registry); T Threlfall (Western Australian Cancer Registry); D Currow*, 
H You (Cancer Institute NSW); New Zealand: C Lewis, SA Miles (New Zealand Cancer 
Registry).
*CONCORD Steering Committee. †Sergio Koifman passed away on May 21, 2014.
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Panel: Research in context
Systematic review
In the first global comparison of population-based cancer survival (CONCORD),6 wide 
variations in survival from cancers of the breast (women), colon, rectum, and prostate 
were reported among 1·9 million adults diagnosed during 1990–94 and followed up to 
1999 in 31 countries (16 countries had national coverage). More recent studies have 
differed with respect to geographic and population coverage, calendar period, and 
analytical methods, and they do not enable worldwide comparison of survival trends.7–9 
With CONCORD-2, we have extended coverage to 25·7 million cancer patients 
diagnosed during the 15-year period 1995–2009 in one of 67 countries (26 of low or 
middle income), of which 40 countries had national coverage.
Interpretation
The ten index cancers we selected for analysis represent two-thirds of the overall cancer 
burden in both low-income and high-income countries. 5-year survival from colon, rectal, 
and breast cancers has increased in most developed countries. Liver and lung cancer 
remain lethal in both developing and developed countries. Striking increases in prostate 
cancer survival have occurred in many countries, but trends vary widely. The range in 
cervical and ovarian cancer survival is very wide, but improvements have been slight. In 
east Asia, stomach cancer survival is very high, suggesting lessons could be learnt, 
whereas survival for adult and childhood leukaemia is remarkably low. The global range 
in survival from precursor-cell acute lymphoblastic leukaemia in children is very wide, 
suggesting major deficiencies in the management of what is now a largely curable 
disease. The findings of our study can be used to assess the extent to which investment in 
health-care systems is improving their effectiveness.
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Figure 1. Participating countries and regions (adults)
National registries in smaller countries are shown in boxes at different scales. 28 regional 
maps and a world map for childhood acute lymphoblastic leukaemia are in the appendix (pp 
112–40).
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Figure 2. Global distribution of age-standardised 5-year net survival for women diagnosed with 
breast cancer during 1995–99, 2000–04, and 2005–09, by continent and country
Age-standardised 5-year net survival estimates for other cancers are presented in the 
appendix (pp 141–51). Survival estimates for every country are ranked from highest to 
lowest within every continent; for ease of reference, the ranking for 2005–09 is used for 
1995–99 and 2000–04. Error bars represent 95% CIs. Grey bars represent African countries; 
red bars represent America (Central and South); light green bars represent America (North); 
purple bars represent Asian countries; blue bars represent European countries; and dark 
green bars represent Oceania. *100% coverage of the national population. †National 
estimate not age-standardised. §National estimate flagged as less reliable because the only 
estimate or estimates available are from a registry or registries in this category.
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Figure 3. Trends in age-standardised 5-year net survival for women diagnosed with breast 
cancer during 1995–99, 2000–04, and 2005–09, by continent or region and country
Trends in age-standardised 5-year net survival for other cancers are presented in the 
appendix (pp 152–62). Countries have been grouped into 12 geographical regions. 
ARG=Argentina. AUS=Australia. AUT=Austria. BEL=Belgium. BGR=Bulgaria. 
BRA=Brazil. CAN=Canada. CHE=Switzerland. CHL=Chile. CHN=China. COL=Colombia. 
CUB=Cuba. CYP=Cyprus. CZE=Czech Republic. DEU=Germany. DNK=Denmark. 
DZA=Algeria. ECU=Ecuador. ESP=Spain. EST=Estonia. FIN=Finland. FRA=France. 
GBR=United Kingdom. GIB=Gibraltar. GMB=The Gambia. HRV=Croatia. IDN=Indonesia. 
IND=India. IRL=Ireland. ISL=Iceland. ISR=Israel. ITA=Italy. JOR=Jordan. JPN=Japan. 
KOR=South Korea. LBY=Libya. LTU=Lithuania. LVA=Latvia. MLI=Mali. MLT=Malta. 
MNG=Mongolia. MUS=Mauritius. MYS=Malaysia. NLD=Netherlands. NOR=Norway. 
NZL=New Zealand. POL=Poland. PRI=Puerto Rico. PRT=Portugal. QAT=Qatar. 
ROU=Romania. RUS=Russia. SAU=Saudi Arabia. SVK=Slovakia. SVN=Slovenia. 
SWE=Sweden. TWN=Taiwan. THA=Thailand. TUN=Tunisia. TUR=Turkey. USA=United 
States of America. ZAF=South Africa. §Continent or region with one or more national 
estimates flagged as less reliable.
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Figure 4. Global range of age-standardised 5-year net survival estimates for women diagnosed 
with breast cancer in 228 cancer registries
Each box-plot shows the range of survival estimates among all those cancer registries for 
which suitable estimates could be obtained for patients diagnosed in a given calendar period 
in each continent. The number of registries included in each box-plot is shown in 
parentheses. Survival estimates considered less reliable are not included. The vertical line 
inside each box denotes the median survival value, and the box shows the IQR between the 
lower and upper quartiles. The extreme limits of the box-plot are 1·5 times the IQR below 
the lower quartile and above the upper quartile. Open circles indicate outlier values, outside 
this range. Data for other cancers are presented in the appendix (pp 163–73).
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Table 1
Definition of malignant diseases
Topography or morphology codes* Description
Stomach C16·0–C16·6, C16·8–C16·9 Stomach
Colon C18·0–C18·9, C19·9 Colon and rectosigmoid junction
Rectum C20·9, C21·0–C21·2, C21·8 Rectum, anus, and anal canal
Liver C22·0–C22·1 Liver and intrahepatic bile ducts
Lung C34·0–C34·3, C34·8–C34·9 Lung and bronchus
Breast (women) C50·0–C50·6, C50·8–C50·9 Breast
Cervix C53·0–C53·1, C53·8–C53·9 Cervix uteri
Ovary† C48·0–C48·2, C56·9, C57·0–C57·4, C57·7–C57·9 Ovary, fallopian tube, and uterine ligaments, 
other and unspecified female genital organs, 
peritoneum and retroperitoneum
Prostate C61·9 Prostate gland
Leukaemia (adults)‡ 9670, 9687, 9727, 9728, 9729, 9800, 9801, 9805, 9820, 9823, 9826, 
9832, 9833, 9835, 9836, 9837, 9840, 9860, 9861, 9866, 9867, 9870, 
9871, 9872, 9873, 9874, 9891, 9895, 9896, 9897, 9910, 9920, 9930, 
9931, 9940, 9984, 9987
Leukaemia
Leukaemia (children)‡ 9727, 9728, 9729, 9835, 9836, 9837 Precursor-cell acute lymphoblastic leukaemia
*
International Classification of Diseases for Oncology, 3rd edn (ICD-O-3).19 We defined solid tumours with topography (anatomical site) codes.
†
Includes peritoneum and retroperitoneum (C48·0–C48·2), where ovarian cancers of high-grade serous morphology are frequently detected; also 
includes the fallopian tube, uterine ligaments, and adnexa (C57·0–C57·4), and other and unspecified female genital organs (C57·7–C57·9).
‡We defined adult leukaemia subtypes with morphology codes in HAEMACARE groups 6, 11, 15, 17, 18, 19, 20, 21, and 22 (appendix p 2).20 
The six morphology codes used to define precursor-cell acute lymphoblastic leukaemia (referred to as acute lymphoblastic leukaemia) in children 
are those in HAEMACARE group 15 only.
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